Lung Health Study II

• Status: Completed
• Trial end date: 1999-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if participants with chronic obstructive pulmonary disease, who were assigned to inhaled corticosteroids had a lower rate of decline in lung function and lower incidence of respiratory morbidity compared to participants assigned to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion:

1. Previously participated in or screened for the Lung Health Study I

2. Ages 40 to 69

3. Forced expiratory volume at one second (FEV1)/forced vital capacity(FVC) < 70 percent

4. Forced expiratory volume at one second (FEV1) 30 to 90 percent predicted.

Exclusions:

1. Cancer

2. Recent myocardial infarction

3. Alcoholism

4. Heart Failure

5. Insulin-dependent diabetes mellitus

6. Neuropsychiatric disorders

7. Used bronchodilators or oral or inhaled corticosteroids in previous year